Thyroid hormone, thyroid hormone receptors, and cancer: a clinical perspective
The DOI matches its Crossref record; 79 of the 79 references it cites were found in a registry or an index.
Abstract
Thyroid hormones (THs) may play a role in diseases other than hyper- and hypothyroidism. Several lines of evidence suggest tumor-promoting effects of TH and TH receptors. They are possibly mediated by phosphatidylinositol-3-kinase and MAPK and involve among others stimulation of angiogenesis via αvβ3. Thus, an increased risk for colon, lung, prostate, and breast cancer with lower TSH has been demonstrated in epidemiological studies, even suggesting a TH dose effect on cancer occurrence. Furthermore, higher TH levels were associated with an advanced clinical stage of breast and prostate cancer. In rodent models, TH stimulated growth and metastasis of tumor transplants, whereas hypothyroidism had opposite effects. In clinical studies of glioblastoma and head and neck cancer, hypothyroid patients showed longer survival than euthyroid patients. Also, patients with renal cell cancer that were treated with the tyrosine kinase inhibitor sunitinib and developed hypothyroidism in due course showed significantly longer survival than patients that remained euthyroid. Development of hypothyroidism was an independent predictor for survival in two studies. Yet, it is still possible that hypothyroidism is only a surrogate marker for treatment efficacy and does not positively influence treatment outcome by itself. Future cancer treatment studies, especially with substances that can induce hypothyroidism, should therefore be designed in a way that allows for an analysis of thyroid function status and its contribution on treatment outcome.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Thyroid dysfunction, mostly hypothyroidism, is an adverse effect of checkpoint inhibitor treatment for cancer, and has been associated with longer survival in these studies (36,37).”
From Evidence-Based Use of Levothyroxine/Liothyronine Combinations in Treating Hypothyroidism: A Consensus Document (2021) · cites this paper as [37]
In the citing paper
“Thyroid dysfunction, mostly hypothyroidism, is an adverse effect of checkpoint inhibitor treatment for cancer, and has been associated with longer survival in these studies [36, 37].”
From Evidence-Based Use of Levothyroxine/Liothyronine Combinations in Treating Hypothyroidism: A Consensus Document (2021) · cites this paper as [37]
Citations
Cites
Physiological and Molecular Basis of Thyroid Hormone Action
Yen, P. M. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.3.1097 · Cited by 2,011 · cited 1×
“Two different genes, THRA on chromosome 17 and THRB on chromosome 3, encode TRa and TRb respectively (Yen 2001).”
BackgroundDefining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics
Semenza, G. L. (2010) · Oncogene · doi:10.1038/onc.2009.441 · Cited by 1,712
Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase
Simoncini, T., Hafezi-Moghadam, A., Brazil, D. P., Ley, K., Chin, W. W., & Liao, J. K. (2000) · Nature · doi:10.1038/35035131 · Cited by 1,436 · cited 1×
“…that TH and TRb could also act through a different mechanism: the ligand-bound TRb could activate the phosphatidylinositol-3-kinase (PI3K) pathway via phosphorylation of Akt/PKB within minutes, which subsequently affected gene expression (Simoncini et al. 2000, Lei et al. 2004, Cao et al. 2005).”
BackgroundMolecular Aspects of Thyroid Hormone Actions
Cheng, S.-Y., Leonard, J. L., & Davis, P. J. (2010) · Endocrine Reviews · doi:10.1210/er.2009-0007 · Cited by 1,384 · cited 1×
“In addition, truncated TR isoforms exist that lack amino terminal domains and DNA binding (Cheng et al. 2010).”
BackgroundPTEN and the PI3-Kinase Pathway in Cancer
Chalhoub, N., & Baker, S. J. (2009) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathol.4.110807.092311 · Cited by 1,245 · cited 1×
“And the oncogenic PI3K pathway, activated by TH via TRa/b and the S1 site of avb3, facilitates cell growth and survival and inhibits apoptosis (Chalhoub & Baker 2009).”
BackgroundBergh, J. J., Lin, H.-Y., Lansing, L., Mohamed, S. N., Davis, F. B., Mousa, S., & Davis, P. J. (2005) · Endocrinology · doi:10.1210/en.2005-0102 · Cited by 497
Rapid nongenomic actions of thyroid hormone
Hiroi, Y., Kim, H.-H., Ying, H., Furuya, F., Huang, Z., Simoncini, T., Noma, K., Ueki, K., Nguyen, N.-H., Scanlan, T. S., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0601600103 · Cited by 380 · cited 1×
“Cao et al. (2009) could demonstrate PI3K activation in TRa overexpressing neuronal cells and Hiroi et al. (2006) found TRa1 association with p85a followed by phosphorylation of Akt/PKB, a downstream target of PI3K, and activation of endothelial nitric oxide synthase. avb3 as TR Bergh et al. (2005)…”
BackgroundA Mutation in the Thyroid Hormone Receptor Alpha Gene
Bochukova, E., Schoenmakers, N., Agostini, M., Schoenmakers, E., Rajanayagam, O., Keogh, J. M., Henning, E., Reinemund, J., Gevers, E., Sarri, M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110296 · Cited by 379 · cited 1×
“The clinical differences between patients with resistance to TH (RTH) due to TRb and TRa mutations further demonstrate that distinct physiological roles for the TR isoforms exist (Refetoff & Dumitrescu 2007, Bochukova et al. 2012, Ferrara et al. 2012, van Mullem et al. 2012).”
BackgroundFactors Related to Inflammation of the Ovarian Epithelium and Risk of Ovarian Cancer
Ness, R. B., Grisso, J. A., Cottreau, C., Klapper, J., Vergona, R., Wheeler, J. E., Morgan, M., & Schlesselman, J. J. (2000) · Epidemiology · doi:10.1097/00001648-200003000-00006 · Cited by 363 · cited 2×
“history of ovarian cancer) (Ness et al. 2000).”
BackgroundInfluentialA Mutation in the Thyroid Hormone Receptor Alpha Gene
Bochukova, E. G., Schoenmakers, N. A., Agostini, M., Schoenmakers, E., Rajanayagam, O., Keogh, J. M., Henning, E., Reinemund, J., Gevers, E. F., Sarri, M., et al. (2012) · UCL Discovery (University College London) · Cited by 327
Refetoff, S., & Dumitrescu, A. M. (2007) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2007.03.005 · Cited by 295 · cited 1×
“Four hypothyroid patients were placed on T4 supplementation (Reid et al. 1991).”
BackgroundKaneshige, M., Kaneshige, K., Zhu, X.-G., Dace, A., Garrett, L., Carter, T. A., Kazlauskaite, R., Pankratz, D. G., Wynshaw-Boris, A., Refetoff, S., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.230285997 · Cited by 268 · cited 3×
“This mutant completely lost T3 binding ability, showed no transactivation activity, and exerted a strong dominant negative effect (Kaneshige et al. 2000).”
BackgroundInfluentialWeiss, R. E., & Refetoff, S. (2000) · Reviews in Endocrine and Metabolic Disorders · doi:10.1023/a:1010072605757 · Cited by 258
Lin, H.-Y., Sun, M., Tang, H.-Y., Lin, C., Luidens, M. K., Mousa, S. A., Incerpi, S., Drusano, G. L., Davis, F. B., & Davis, P. J. (2009) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00305.2008 · Cited by 255
Hypoxia-inducible factor-1 in human breast and prostate cancer
Kimbro, K. S., & Simons, J. W. (2006) · Endocrine-Related Cancer · doi:10.1677/erc.1.00728 · Cited by 249 · cited 1×
“HIF1a expression is a prognostic marker in renal cell carcinoma (RCC) and breast and prostate cancer, among others (Kimbro & Simons 2006).”
BackgroundCao, X., Kambe, F., Moeller, L. C., Refetoff, S., & Seo, H. (2005) · Molecular Endocrinology · doi:10.1210/me.2004-0093 · Cited by 246 · cited 4×
“The importance of PI3K-Akt overactivation in the TRbPV/PV http://erc.endocrinology-journals.org q 2013 Society for Endocrinology DOI: 10.1530/ERC-12-0219 Printed in Great Britain mice is highlighted by the fact that treatment with LY294002, a potent PI3K inhibitor, significantly decreased vascular invasion and prevent…”
BackgroundResultInfluentialSelf-citationMannavola, D., Coco, P., Vannucchi, G., Bertuelli, R., Carletto, M., Casali, P. G., Beck-Peccoz, P., & Fugazzola, L. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0586 · Cited by 227 · cited 2×
“2011) or inhibition of iodine uptake (Mannavola et al. 2007).”
BackgroundDavis, F. B., Mousa, S. A., O’Connor, L., Mohamed, S., Lin, H.-Y., Cao, H. J., & Davis, P. J. (2004) · Circulation Research · doi:10.1161/01.res.0000130784.90237.4a · Cited by 225 · cited 1×
“TH can, via avb3/S2, activate ERK1/2 and induce fibroblast growth factor 2 and promote angiogenesis, also crucial for rapid tumor growth (Davis 2004).”
BackgroundClinical Phenotype and Mutant TRα1
van Mullem, A., van Heerebeek, R., Chrysis, D., Visser, E., Medici, M., Andrikoula, M., Tsatsoulis, A., Peeters, R., & Visser, T. J. (2012) · New England Journal of Medicine · doi:10.1056/nejmc1113940 · Cited by 223 · cited 1×
“The clinical differences between patients with resistance to TH (RTH) due to TRb and TRa mutations further demonstrate that distinct physiological roles for the TR isoforms exist (Refetoff & Dumitrescu 2007, Bochukova et al. 2012, Ferrara et al. 2012, van Mullem et al. 2012).”
BackgroundCristofanilli, M., Yamamura, Y., Kau, S., Bevers, T., Strom, S., Patangan, M., Hsu, L., Krishnamurthy, S., Theriault, R. L., & Hortobagyi, G. N. (2005) · Cancer · doi:10.1002/cncr.20881 · Cited by 216 · cited 1×
“Cristofanilli et al. (2005) retrospectively studied the prevalence of hypothyroidism in patients with breast cancer.”
BackgroundMembrane Receptor for Thyroid Hormone: Physiologic and Pharmacologic Implications
Davis, P. J., Davis, F. B., Mousa, S. A., Luidens, M. K., & Lin, H.-Y. (2011) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010510-100512 · Cited by 204 · cited 1×
“…nitric oxide synthase. avb3 as TR Bergh et al. (2005) demonstrated that T4 and T3 could bind to a purified plasma membrane protein, the integrin avb3. avb3 contains two TH binding sites, denoted as S1 and S2, which translate the TH signal differently (Davis et al. 2011, Freindorf et al. 2012).”
BackgroundHypothyroidism in patients with renal cell carcinoma: Blessing or curse?
Schmidinger, M., Vogl, U. M., Bojic, M., Lamm, W., Heinzl, H., Haitel, A., Clodi, M., Kramer, G., & Zielinski, C. C. (2011) · Cancer · doi:10.1002/cncr.25422 · Cited by 192
Suzuki, H., Willingham, M. C., & Cheng, S.-Y. (2002) · Thyroid · doi:10.1089/105072502320908295 · Cited by 190 · cited 1×
“The enlargement of the thyroid in the homozygous TRbPV/PV mice began at 3 weeks and reached 19- and 36-fold the weight of WT mice at ages 5–7 and O12 months respectively (Suzuki et al. 2002).”
BackgroundSteroid hormone transforming aldo–keto reductases and cancer
Penning, T. M., & Byrns, M. C. (2009) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.03700.x · Cited by 181 · cited 1×
“…study of T3-induced gene expression in human skin fibroblasts were the aldo-keto reductases 1–3 (AKR1C1–3; Moeller et al. 2005b), which are associated with aggressiveness of prostate cancer due to increased conversion of adrenal androgens to testosterone (Fung 2006, Penning & Byrns 2009).”
BackgroundA Phase II Trial of Imatinib Therapy for Metastatic Medullary Thyroid Carcinoma
de Groot, J. W. B., Zonnenberg, B. A., van Ufford-Mannesse, P. Q., de Vries, M. M., Links, T. P., Lips, C. J. M., & Voest, E. E. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0649 · Cited by 180 · cited 1×
“Extrathyroidal mechanisms affecting TH metabolism must also be involved because patients with medullary thyroid cancer treated with imatinib, who underwent thyroidectomy and were on T4 replacement therapy, also developed hypothyroidism (de Groot et al. 2007).”
BackgroundThyroid Function and Cancer Risk: A Prospective Population Study
Hellevik, A. I., Åsvold, B. O., Bjøro, T., Romundstad, P. R., Nilsen, T. I. L., & Vatten, L. J. (2009) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-08-0911 · Cited by 178 · cited 1×
“Another prospective study assessed a connection of thyroid function with cancer risk: participants of the Nord-Trøndelag Health Study were studied for TH and TSH levels and cancer incidence (Hellevik et al. 2009).”
BackgroundHassan, M. M., Kaseb, A., Li, D., Patt, Y. Z., Vauthey, J.-N., Thomas, M. B., Curley, S. A., Spitz, M. R., Sherman, S. I., Abdalla, E. K., et al. (2009) · Hepatology · doi:10.1002/hep.22793 · Cited by 173 · cited 1×
“Women, but not men, with a history of hypothyroidism had a 2.8-fold higher risk of HCC than participants without a history of hypothyroidism (after adjustment for age, race, diabetes, smoking, alcohol consumption, family history of cancer, and HBV/HCV status) (Hassan et al. 2009).”
BackgroundInfluentialActivation of phosphatidylinositol 3-kinase signaling by a mutant thyroid hormone β receptor
Furuya, F., Hanover, J. A., & Cheng, S.-Y. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510849103 · Cited by 149 · cited 2×
“The TRbPV mutant bound significantly stronger to the regulating subunit of PI3K than WT TRb, leading to stronger activation of PI3K and downstream kinases (mTOR, AKT, and p70S6K) (Furuya et al. 2006).”
BackgroundFunctionally Impaired TR Mutants Are Present in Thyroid Papillary Cancer
Puzianowska‐Kuźnicka, M., Krystyniak, A., Madej, A., Cheng, S.-Y., & Nauman, J. A. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.3.8296 · Cited by 137 · cited 1×
“…more prevalent in patients with HCC of unknown etiology than in HCC patients with alcoholic liver disease or HCV in another case–control study (Reddy et al. 2007), suggesting 2 Sarcoma (S1), fibrosarcoma (T241) Murine No treatment vs ment vs 131I-in hypothyroidis 3 Morris hepatoma 44 Rat No…”
BackgroundYen, P. M., Feng, X., Flamant, F., Chen, Y., Walker, R. L., Weiss, R. E., Chassande, O., Samarut, J., Refetoff, S., & Meltzer, P. S. (2003) · EMBO Reports · doi:10.1038/sj.embor.embor862 · Cited by 137 · cited 1×
“Studies from TR knockout mice and stably transformed HepG2 cells showed largely overlapping gene expression patterns of positively regulated genes for TRa and TRb, suggesting that TR amount, rather than isoform type, is important (Yen et al. 2003).”
BackgroundHercbergs, A. A., Goyal, L. K., Suh, J. H., Lee, S., Reddy, C. A., Cohen, B. H., Stevens, G. H. J., Reddy, S. K., Peereboom, D. M., Elson, P. J., et al. (2003) · PubMed · Cited by 135
Moeller, L. C., Dumitrescu, A. M., & Refetoff, S. (2005) · Molecular Endocrinology · doi:10.1210/me.2004-0542 · Cited by 131 · cited 3×
“ZAKI-4a induction by T3 is dependent on TRb and could be blocked by PI3K inhibitors, such as LY294002 (Cao et al. 2005, Moeller et al. 2005b).”
BackgroundSelf-citationFung, K.-M., Samara, E. N. S., Wong, C., Metwalli, A., Krlin, R., Bane, B., Liu, C. Z., Yang, J. T., Pitha, J. V., Culkin, D. J., et al. (2006) · Endocrine Related Cancer · doi:10.1677/erc.1.01048 · Cited by 129 · cited 1×
“…study of T3-induced gene expression in human skin fibroblasts were the aldo-keto reductases 1–3 (AKR1C1–3; Moeller et al. 2005b), which are associated with aggressiveness of prostate cancer due to increased conversion of adrenal androgens to testosterone (Fung 2006, Penning & Byrns 2009).”
BackgroundExpression of mutant thyroid hormone nuclear receptors in human hepatocellular carcinoma cells
Lin, K., Shieh, H.-Y., Chen, S. L., & Hsu, H.-C. (1999) · Molecular Carcinogenesis · doi:10.1002/(sici)1098-2744(199909)26:1<53::aid-mc7>3.0.co;2-z · Cited by 123
Yalçın, M., Dyskin, E., Lansing, L., Bharali, D. J., Mousa, S. S., Bridoux, A., Hercbergs, A. H., Lin, H., Davis, F. B., Glinsky, G. V., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1926 · Cited by 120 · cited 16×
“Similarly, of 15 cancer patients (RCC, malignant melanoma) treated with IL2 and lymphokine-activated killer cells, five of seven hypothyroid patients responded with partial or complete remission, but none of the euthyroid patients (Weijl et al. 1993).”
BackgroundInfluentialRiesenbeck, L., Bierer, S., Hoffmeister, I., Köpke, T., Papavassilis, P. M., Hertle, L., Thielen, B., & Herrmann, E. M. (2010) · World Journal of Urology · doi:10.1007/s00345-010-0627-2 · Cited by 118 · cited 1×
“The main consequences appear to be impaired T3 binding and altered recognition of promoter sequences, leading to regulation of a set of genes distinct from that regulated by the wild-type receptors (Rosen & Privalsky 2011).”
BackgroundAKT Activation Promotes Metastasis in a Mouse Model of Follicular Thyroid Carcinoma
Kim, C. S., Vasko, V. V., Kato, Y., Kruhlak, M. J., Saji, M., Cheng, S.-Y., & Ringel, M. D. (2005) · Endocrinology · doi:10.1210/en.2005-0172 · Cited by 114 · cited 2×
“Because the TRbPV mutant constitutively activates PI3K and subsequently Akt, phosphorylation status of these kinases was tested in the TRb mice (Kim et al. 2005).”
BackgroundKamiya, Y., Puzianowska‐Kuźnicka, M., McPhie, P., Nauman, J., Cheng, S.-Y., & Nauman, A. (2002) · Carcinogenesis · doi:10.1093/carcin/23.1.25 · Cited by 112
Ferrara, A. M., Onigata, K., Ercan, O., Woodhead, H., Weiss, R. E., & Refetoff, S. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2642 · Cited by 110 · cited 1×
“The clinical differences between patients with resistance to TH (RTH) due to TRb and TRa mutations further demonstrate that distinct physiological roles for the TR isoforms exist (Refetoff & Dumitrescu 2007, Bochukova et al. 2012, Ferrara et al. 2012, van Mullem et al. 2012).”
BackgroundYalçın, M., Bharali, D. J., Lansing, L., Dyskin, E., Mousa, S. S., Hercbergs, A. A., Davis, F. B., Davis, P. J., & Mousa, S. A. (2009) · PubMed · Cited by 106
Kappers, M. H. W., van Esch, J. H. M., Smedts, F. M. M., de Krijger, R. R., Eechoute, K., Mathijssen, R. H. J., Sleijfer, S., Leijten, F., Danser, A. H. J., van den Meiracker, A. H., et al. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1172 · Cited by 104 · cited 3×
“2011), and capillary rarefication (Kappers et al. 2011) or inhibition of iodine uptake (Mannavola et al.”
BackgroundFuruya, F., Lu, C., Willingham, M. C., & Cheng, S.-Y. (2007) · Carcinogenesis · doi:10.1093/carcin/bgm174 · Cited by 103 · cited 2×
“This led to significantly longer median survival of the LY-treated compared with untreated TRb mice with 329G65 vs 244G63 days respectively (Furuya et al. 2007).”
ResultReddy, A., Dash, C., Leerapun, A., Mettler, T. A., Stadheim, L. M., Lazaridis, K. N., Roberts, R. O., & Roberts, L. R. (2006) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2006.07.011 · Cited by 102 · cited 1×
“The clinical differences between patients with resistance to TH (RTH) due to TRb and TRa mutations further demonstrate that distinct physiological roles for the TR isoforms exist (Refetoff & Dumitrescu 2007, Bochukova et al. 2012, Ferrara et al. 2012, van Mullem et al. 2012).”
BackgroundWeijl, N. I., Harst, D. V. D., Brand, A., Kooy, Y. M. C., Luxemburg, S. V., Schroder, J., Lentjes, E. G. W. M., ROOD, J. J. V., Cleton, F. J., & Osanto, S. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.7.1376 · Cited by 99 · cited 1×
“Similarly, of 15 cancer patients (RCC, malignant melanoma) treated with IL2 and lymphokine-activated killer cells, five of seven hypothyroid patients responded with partial or complete remission, but none of the euthyroid patients (Weijl et al. 1993).”
BackgroundTosovic, A., Bondeson, A., Bondeson, L., Ericsson, U., Malm, J., & Manjer, J. (2010) · Breast Cancer Research · doi:10.1186/bcr2587 · Cited by 96 · cited 2×
“3 years (Tosovic et al. 2010).”
BackgroundInfluentialLei, J., Mariash, C. N., & Ingbar, D. H. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m405497200 · Cited by 94 · cited 1×
“…that TH and TRb could also act through a different mechanism: the ligand-bound TRb could activate the phosphatidylinositol-3-kinase (PI3K) pathway via phosphorylation of Akt/PKB within minutes, which subsequently affected gene expression (Simoncini et al. 2000, Lei et al. 2004, Cao et al. 2005).”
BackgroundPTEN deficiency accelerates tumour progression in a mouse model of thyroid cancer
Guigon, C. J., Zhao, L., Willingham, M. C., & Cheng, S.-Y. (2009) · Oncogene · doi:10.1038/onc.2008.407 · Cited by 92 · cited 2×
“To test whether reducing PTEN further increased tumor growth, mice haplodeficient for PTEN were crossed with the PV mice (TRbPV/PVPtenC/K mice) (Guigon et al. 2009).”
BackgroundHypothyroidism Enhances Tumor Invasiveness and Metastasis Development
Martínez-Iglesias, O. A., García-Silva, S., Regadera, J., & Aranda, A. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006428 · Cited by 90 · cited 2×
“…PTU group Theodossiou et al. (1999) induced m Reduced tumor growth and proliferation, but enhanced invasiveness and metastasis in hypothyroid mice Martinez-Iglesias et al. (2009) Published by Bioscientifica Ltd. Downloaded from Bioscientifica.com at 09/17/2019 08:20:05AM via free access E n d o…”
BackgroundResultInfluentialNelson, M., Hercbergs, A., Rybicki, L., & Strome, M. (2006) · Archives of Otolaryngology–Head & Neck Surgery · doi:10.1001/archotol.132.10.1041 · Cited by 89 · cited 1×
“Nelson et al. (2006) analyzed retrospectively whether thyroid function is associated with treatment outcome in head and neck squamous cell cancer.”
BackgroundChan, I. H., & Privalsky, M. L. (2009) · Molecular Endocrinology · doi:10.1210/me.2009-0025 · Cited by 88 · cited 1×
“Yet, the TR isoforms show differential DNA binding affinity to promoters and the transcriptional response of a gene on a given tissue may depend on the predominant TR isoform (Chan & Privalsky 2009, Chiamolera et al. 2012).”
BackgroundTransforming growth factor-? responsiveness inDPC4/SMAD4-null cancer cells
Dai, J. L., Schutte, M., Bansal, R. K., Wilentz, R. E., Sugar, A. Y., & Kern, S. E. (1999) · Molecular Carcinogenesis · doi:10.1002/(sici)1098-2744(199909)26:1<37::aid-mc5>3.0.co;2-6 · Cited by 88
Endocrine side effects of broad-acting kinase inhibitors
Lodish, M. B., & Stratakis, C. A. (2010) · Endocrine Related Cancer · doi:10.1677/erc-10-0082 · Cited by 88 · cited 1×
“%) of patients on sunitinib treatment developing hypothyroidism (Lodish & Stratakis 2010, Brown 2011).”
BackgroundMousa, S. A., Yalçın, M., Bharali, D. J., Meng, R., Tang, H.-Y., Lin, H., Davis, F. B., & Davis, P. J. (2011) · Lung Cancer · doi:10.1016/j.lungcan.2011.10.003 · Cited by 85 · cited 2×
“For example, T4 and T3 stimulated proliferation of human non-small cell lung cancer cells (NSCLC, NCI-H1299) in a concentration-dependent manner as measured by PCNA accumulation (Mousa et al. 2012).”
BackgroundMethodThyroid Hormone Responsive Genes in Cultured Human Fibroblasts
Moeller, L. C., Dumitrescu, A. M., Walker, R. L., Meltzer, P. S., & Refetoff, S. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1768 · Cited by 82 · cited 3×
“ZAKI-4a induction by T3 is dependent on TRb and could be blocked by PI3K inhibitors, such as LY294002 (Cao et al. 2005, Moeller et al. 2005b).”
BackgroundSelf-citationMondul, A. M., Weinstein, S. J., Bosworth, T., Remaley, A. T., Virtamo, J., & Albanes, D. (2012) · PLoS ONE · doi:10.1371/journal.pone.0047730 · Cited by 80 · cited 1×
“006) (Mondul et al. 2012).”
Could thyroid dysfunction influence outcome in sunitinib-treated metastatic renal cell carcinoma?
Sabatier, R., Eymard, J. C., Walz, J. C., Deville, J., Narbonne, H., Boher, J., Salem, N., Marcy, M., Brunelle, S., Viens, P., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr275 · Cited by 69
Baldazzi, V., Tassi, R., Lapini, A., Santomaggio, C., Carini, M., & Mazzanti, R. (2010) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2010.07.015 · Cited by 67 · cited 1×
“%) developed hypothyroidism as defined by at least one elevated TSH level (Baldazzi et al. 2012).”
BackgroundCao, X., Kambe, F., Yamauchi, M., & Seo, H. (2009) · Biochemical Journal · doi:10.1042/bj20090643 · Cited by 65 · cited 1×
“Cao et al. (2009) could demonstrate PI3K activation in TRa overexpressing neuronal cells and Hiroi et al. (2006) found TRa1 association with p85a followed by phosphorylation of Akt/PKB, a downstream target of PI3K, and activation of endothelial nitric oxide synthase. avb3 as TR Bergh et al. (2005)…”
BackgroundYalçın, M., Bharali, D. J., Dyskin, E., Dier, E., Lansing, L., Mousa, S. S., Davis, F. B., Davis, P. J., & Mousa, S. A. (2010) · Thyroid · doi:10.1089/thy.2009.0249 · Cited by 63 · cited 16×
“Similarly, of 15 cancer patients (RCC, malignant melanoma) treated with IL2 and lymphokine-activated killer cells, five of seven hypothyroid patients responded with partial or complete remission, but none of the euthyroid patients (Weijl et al. 1993).”
BackgroundInfluentialChiamolera, M. I., Sidhaye, A. R., Matsumoto, S., He, Q., Hashimoto, K., Ortiga-Carvalho, T. M., & Wondisford, F. E. (2012) · Molecular Endocrinology · doi:10.1210/me.2011-1290 · Cited by 62 · cited 1×
“Yet, the TR isoforms show differential DNA binding affinity to promoters and the transcriptional response of a gene on a given tissue may depend on the predominant TR isoform (Chan & Privalsky 2009, Chiamolera et al. 2012).”
BackgroundShinohara, N., Takahashi, M., Kamishima, T., Ikushima, H., Otsuka, N., Ishizu, A., Shimizu, C., Kanayama, H., & Nonomura, K. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6606029 · Cited by 58
Propylthiouracil-induced hypothyroidism reduces xenograft tumor growth in athymic nude mice
Theodossiou, C., Skrepnik, N., Robert, E. G., Prasad, C., Axelrad, T. W., Schapira, D. V., & Hunt, J. D. (1999) · Cancer · doi:10.1002/(sici)1097-0142(19991015)86:8<1596::aid-cncr30>3.0.co;2-c · Cited by 51
Mishkin, S., Pollack, R. S., Yalovsky, M. A., Morris, H. P., & Mishkin, S. (1981) · PubMed · Cited by 49
Tyrosine kinase inhibitor-induced hypothyroidism: incidence, etiology, and management
Brown, R. L. (2011) · Targeted Oncology · doi:10.1007/s11523-011-0197-2 · Cited by 47 · cited 1×
“%) of patients on sunitinib treatment developing hypothyroidism (Lodish & Stratakis 2010, Brown 2011).”
BackgroundIncidence of thyroid hormone therapy in patients treated with sunitinib or sorafenib: A cohort study
Feldt, S., Schüssel, K., Quinzler, R., Franzmann, A., Czeche, S., Ludwig, W.-D., & Schulz, M. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.01.036 · Cited by 47 · cited 2×
“7%) on sunitinib treatment later received a first prescription for T4 (Feldt et al. 2012).”
BackgroundWolter, P., Stefan, C., Decallonne, B., Dumez, H., Fieuws, S., Wildiers, H., Clement, P., Debaere, D., Van Oosterom, A., & Schöffski, P. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.5126 · Cited by 47 · cited 1×
“A positive correlation between sunitinib-induced hypothyroidism and progression-free (PFS) or overall survival (OS) of RCC patients was first reported in 2008 (Wolter et al. 2008).”
BackgroundTelomere shortening and the clinicopathologic characteristics of human colorectal carcinomas
Takagi, S., Kinouchi, Y., Hiwatashi, N., Chida, M., Nagashima, F., Takahashi, S., Negoro, K., Shimosegawa, T., & Toyota, T. (1999) · Cancer · doi:10.1002/(sici)1097-0142(19991015)86:8<1431::aid-cncr7>3.0.co;2-r · Cited by 47
Rosen, M. D., & Privalsky, M. L. (2011) · Journal of Thyroid Research · doi:10.4061/2011/361304 · Cited by 47
Ko, A. H., Wang, F., & Holly, E. A. (2007) · Cancer Causes & Control · doi:10.1007/s10552-007-9024-6 · Cited by 45 · cited 2×
“and history of diabetes) (Ko et al. 2007).”
BackgroundInfluentialSerum Triiodothyronine is Increased in Men With Prostate Cancer and Benign Prostatic Hyperplasia
Lehrer, S. P., Diamond, E. J., Stone, N. N., Droller, M. J., & Stock, R. G. (2002) · The Journal of Urology · doi:10.1016/s0022-5347(05)64161-4 · Cited by 43 · cited 2×
“(Lehrer et al. 2002).”
BackgroundEnhancing effect of thyroxine on tumor growth and metastases in syngeneic mouse tumor systems.
Kumar, M. S., Chiang, T., & Deodhar, S. D. (1979) · PubMed · Cited by 41
Combined QM/MM Study of Thyroid and Steroid Hormone Analogue Interactions with Integrin
Freindorf, M., Furlani, T. R., Kong, J., Cody, V., Davis, F. B., & Davis, P. J. (2012) · Journal of Biomedicine and Biotechnology · doi:10.1155/2012/959057 · Cited by 38 · cited 1×
“…nitric oxide synthase. avb3 as TR Bergh et al. (2005) demonstrated that T4 and T3 could bind to a purified plasma membrane protein, the integrin avb3. avb3 contains two TH binding sites, denoted as S1 and S2, which translate the TH signal differently (Davis et al. 2011, Freindorf et al. 2012).”
BackgroundThyroid dysfunction can predict response to immunotherapy with interleukin-2 and interferon-2α
Reid, I., Sharpe, I., McDevitt, J., Maxwell, W., Emmons, R., Tanner, W., & Monson, J. (1991) · British Journal of Cancer · doi:10.1038/bjc.1991.426 · Cited by 31 · cited 1×
“Four hypothyroid patients were placed on T4 supplementation (Reid et al. 1991).”
BackgroundPropylthiouracil Reduces Xenograft Tumor Growth in an Athymic Nude Mouse Prostate Cancer Model
Theodossiou, C., & Schwarzenberger, P. O. (2000) · The American Journal of the Medical Sciences · doi:10.1016/s0002-9629(15)40695-0 · Cited by 31
Lehrer, S. P., Diamond, E., Bajwa, A., Kornreich, R., Stagger, S., Stone, N. N., Droller, M. J., & Rg, S. (2001) · Prostate Cancer and Prostatic Diseases · doi:10.1038/sj.pcan.4500542 · Cited by 29 · cited 1×
“Furthermore, T3 levels were associated with higher clinical stage and risk of recurrence of prostate cancer (Lehrer et al. 2001).”
BackgroundRe: Hypothyroidism in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib
Garfield, D., Hercbergs, A. A., & Davis, P. J. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm008 · Cited by 25 · cited 1×
“There is reasonable concern that substituting these cancer patients with T4 could deprive them of the potential beneficial effects of hypothyroidism (Garfield et al. 2007, 2008).”
BackgroundIncreased survival and inhibition of mammary tumors in hypothyroid mice
Shoemaker, J. P., Bradley, R. L., & Hoffman, R. V. (1976) · Journal of Surgical Research · doi:10.1016/0022-4804(76)90151-7 · Cited by 24
Documentation of Thyroid Function in Clinical Studies With Sunitinib: Why Does It Matter?
Garfield, D. H., Wolter, P., Schöffski, P., Hercbergs, A. A., & Davis, P. J. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.8680 · Cited by 21 · cited 1×
“There is reasonable concern that substituting these cancer patients with T4 could deprive them of the potential beneficial effects of hypothyroidism (Garfield et al. 2007, 2008).”
BackgroundPropylthiouracil Reduces Xenograft Tumor Growth in an Athymic Nude Mouse Prostate Cancer Model
Theodossiou, C., & Schwarzenberger, P. O. (2000) · The American Journal of the Medical Sciences · doi:10.1097/00000441-200002000-00005 · Cited by 13
Research works printed but not linked: 1
- Speranza G Rubinstein L Ivy SP Harris PJ 2011 Correlation between adverse event reports of hypothyroidism and clinical response in patients treated with vascular endothelial growth factor receptor inhibitors (VEGFR-I). Journal of Clinical Oncology29(Supplement: ASCO Meeting Abstracts Part 1) abstract 2602 · doi:10.1200/jco.2011.29.15_suppl.2602
Cited by
de Filette, J., Andreescu, C., Cools, F., Bravenboer, B., & Velkeniers, B. (2019) · Hormone and Metabolic Research · doi:10.1055/a-0843-3366 · Cited by 381
“[134], observations in mouse models suggest that hypothyroidism induced by propylthiouracil suppresses tumor growth, whereas T4 administration had the opposite effect [135, 136].”
BackgroundBelfiore, L., Saunders, D. N., Ranson, M., Thurecht, K. J., Storm, G., & Vine, K. L. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.02.040 · Cited by 294
Thyroid Hormones and Cancer: A Comprehensive Review of Preclinical and Clinical Studies
Krashin, E., Piekiełko-Witkowska, A., Ellis, M., & Ashur-Fabian, O. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00059 · Cited by 217
“A great deal of research has been conducted in recent decades to determine how thyroid hormones exert their growth-promoting effect (7).”
BackgroundJonklaas, J., Bianco, A. C., Cappola, A. R., Celi, F. S., Fliers, E., Heuer, H., McAninch, E. A., Moeller, L. C., Nygaard, B., Sawka, A. M., et al. (2021) · Thyroid® · doi:10.1089/thy.2020.0720 · Cited by 172
“Thyroid dysfunction, mostly hypothyroidism, is an adverse effect of checkpoint inhibitor treatment for cancer, and has been associated with longer survival in these studies (36,37).”
Self-citationHoffman, K., Lorenzo, A., Butt, C. M., Hammel, S. C., Henderson, B. B., Roman, S. A., Scheri, R. P., Stapleton, H. M., & Sosa, J. A. (2017) · Environment International · doi:10.1016/j.envint.2017.06.021 · Cited by 167
“…including thyroid, suggesting that chemicals that disrupt 65 thyroid hormone homeostasis in a significant way could contribute to cancer risk or severity (e.g. 66 Lin et al. 2016; Hellevik et al. 2009; D'Avanzo et al. 2005; Brinton et al. 2007; Søgaard et al 67 2016; Moeller and Führer 2013).”
Background
Metadata
- Authors
- Moeller, L. C., & Führer, D.
- Affiliations
- University of Duisburg-Essen (DE)
- ORCID
- Moeller, Lars C
- Venue
- Endocrine-Related Cancer
- Publisher
- Bioscientifica
- Published
- 2013-04-01
- Volume
- 20
- Issue
- 2
- Pages
- R19-R29
- ISSN
- 1351-0088 (ISSN-L)
- 1479-6821
- OpenAlex
- W2128280017
- Cited by
- 184
- References
- 76
- Citations by year
- 2026: 7 · 2025: 14 · 2024: 16 · 2023: 14 · 2022: 18 · 2021: 18 · 2020: 15 · 2019: 19 · 2018: 13 · 2017: 10 · 2016: 14 · 2015: 18 · 2014: 8
- FWCI
- 1.95
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Endocrine Related Cancer (publishedVersion)
- PubMed (publishedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
- Keywords
- thyroid hormones, thyroid hormone receptor, cancer, hypothyroidism, tumor promotion, phosphatidylinositol 3-kinase, MAPK signaling, angiogenesis, alpha v beta 3 integrin, thyroid-stimulating hormone, colon cancer, lung cancer, prostate cancer, breast cancer, glioblastoma, head and neck cancer, renal cell carcinoma, sunitinib, tyrosine kinase inhibitors, cancer survival, metastasis
- MeSH terms
- Animals, Disease Models, Animal, Humans, Neoplasms, Receptors, Thyroid Hormone, Thyroid Hormones
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.